Kazia Therapeutics Ltd
Kazia Therapeutics Ltd (ASX:KZA) is listed on the Australian Securities Exchange.
See more information about Kazia Therapeutics Ltd
Kazia Therapeutics finishes trial enrolment, sets date for data release
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has completed recruitment for the phase II clinical trial in newly-diagnosed glioblastoma (aggressive brain cancer).
30 patients were recruited at six sites in the US and the final patient commenced dosing on 27 February 2020.
The primary purpose of this study was to transition paxalisib from the very late-stage population that was studied in phase I to the newly-diagnosed patients that represent the target population for the commercial product.
Upcoming data to be presented at cancer conference
Kazia has been accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting in San Diego, CA on 24-29 April 2020.
The AACR meeting is one of the world's largest gatherings of cancer researchers and physicians, and also provides an opportunity for engagement with investors and potential partners.
Kazia anticipates that the AACR poster presentation will provide additional data from the ongoing phase II clinical study, building on the promising signals that were reported in November 2019.
Other Kazia Therapeutics Ltd news
- Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
2020-09-22 - Kazia Therapeutics bringing a vetted drug class to the brain: Edison
2020-09-09 - Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma
2020-08-24 - Kazia Therapeutics raises $1.8 million in well supported share placement
2020-05-06 - Kazia Therapeutics extends SPP owing to strong demand
2020-05-04
